The evaluation of adverse events and theraputic effects using divided CDDP for advanced urothelial carcinoma patients with Chronic Kidney Disease.

The evaluation of adverse events and theraputic effects using divided CDDP for advanced urothelial carcinoma patients with Chronic Kidney Disease. - The evaluation of adverse events and theraputic effects using divided CDDP for advanced urothelial carcinoma patients with Chronic Kidney Disease.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009202

Enrollment

Registered

2012-11-01

Start date

2012-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urothelial Carcinoma

Interventions

using divided CDDP

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: kidney function CCr>30ml/mi,50ml/min>

Exclusion criteria

Exclusion criteria: normal kidney function CCr 30ml/min> insuficient function of organ

Design outcomes

Primary

Measure	Time frame
The evaluation of adverse events	—

Secondary

Measure	Time frame
The evaluation of therapitic effects using RECIST ver 1.1	—

Countries

Japan

Contacts

Public ContactNaoto Sassa

Nagoya University Urology

sassa@med.nagoya-u.ac.jp052-744-2985

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026